The Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)
Northwestern University is one of 25 clinical sites nationwide and the only one in the state of Illinois to take part in this new seven-year initiative created to conduct phase II studies of treatments for neurological diseases through partnerships with academia, private foundations, and industry. The Northwestern grant is a collaboration between Department of Neurology (Tanya Simuni, M.D., PI), Department of Pediatric Neurology/ Ann & Robert H. Lurie Children’s Hospital of Chicago (Leon Epstein, M.D., Co-PI) and Rehabilitation Institute of Chicago (Elliott Roth, M.D., Co-PI). The NeuroNEXT consortium is sponsored by the National Institute of Neurological Disorders and Stroke (NINDS).
NeuroNEXT is a unique new consortium designed to expand NINDS capability to test promising new therapies, increase efficiency of phase II clinical trials, and respond quickly as new opportunities arise to test promising treatments for adult and/or pediatric populations across the spectrum of neurological disorders. The NeuroNEXT model allows Northwestern not only to participate in collaborative studies but also gives NU researchers the opportunity to use the consortium infrastructure to submit their own ideas for neuroscience research.
Additional information about the network and how to submit concept proposals can be found at http://www.neuronext.org.
SMA Biomarkers Study: Spinal Muscular Atrophy (SMA) Biomarkers in the Immediate Postnatal Period of Development
Principal Investigator: Tanya Simuni, MD
Co-PI: Leon Epstein, MD
Co-PI: Elliot Roth, MD
Program Coordinator: Michelle Morley, MS, CCRC
Phone: (312) 503-2465 Email: firstname.lastname@example.org
*Please address all inquires to the Program Coordinator